rs17651213 — MAPT Exon 3 Splice Regulator

MAPT rs17651213 — The Splice Regulator at the Core of Tau Isoform Balance

Within the MAPT gene on chromosome 17, the rs17651213 variant sits in a functionally critical position: it is one of just two intronic polymorphisms that directly control how much tau protein includes its N-terminal exon 3 domain. While the broader H1/H2 haplotype distinction at MAPT has been recognized as a major neurodegenerative disease risk factor for decades, rs17651213 was identified in a landmark 2017 study as one of the molecular levers behind that risk — not merely a passive haplotype marker.

The MAPT gene produces tau, the microtubule-stabilizing protein whose aggregation into neurofibrillary tangles defines a family of neurodegenerative diseases called tauopathies. What makes tau biology especially complex is that the gene produces multiple isoforms through alternative splicing, and the balance between those isoforms — particularly the ratio of 3-repeat (3R) to 4-repeat (4R) tau — differs between healthy brains and diseased ones. The H1 haplotype, tagged by rs17651213's G allele, is consistently found in approximately 94% of progressive supranuclear palsy (PSP) patients compared to about 64% of the general population.

The Mechanism: hnRNP F/Q and Exon 3 Inclusion

A 2017 mechanistic study used whole-locus MAPT genomic DNA vectors to dissect the contribution of individual intronic variants to haplotype-specific tau splicing¹¹ A 2017 mechanistic study used whole-locus MAPT genomic DNA vectors to dissect the contribution of individual intronic variants to haplotype-specific tau splicing
The study expressed H1 and H2 haplotypes with selective allele swaps at rs17651213 and rs1800547 to isolate each variant's contribution, then identified binding proteins by RNA-protein pull-down and mass spectrometry. The researchers identified that both rs17651213 and its partner rs1800547 create distinct RNA-protein binding patterns for two splicing factors: hnRNP F and hnRNP Q.

Crucially, when rs17651213 was swapped alone between haplotype backgrounds — placing the H2 (A) allele into an H1 context — exon 3 inclusion increased 2.52-fold. This makes rs17651213 the dominant driver of the two-SNP regulatory pair: it accounts for more of the exon 3 splicing difference between H1 and H2 than rs1800547 does individually. Overall, the H2 haplotype produces 1.76-fold more exon 3-containing tau transcripts than H1, and knockdown experiments confirmed that hnRNP F and hnRNP Q actively promote H1:H2 differential splicing — reducing both factors increased the H1:H2 exon 3 ratio, while the effects were allele-specific at rs17651213 and rs1800547.

Exon 3 encodes a region of tau's N-terminal projection domain involved in membrane interactions and cytoskeletal attachment. The H1-driven reduction in exon 3 inclusion shifts tau isoform composition toward higher 4-repeat (4R) forms, which are the main tau species in pathological aggregates in PSP and corticobasal degeneration (CBD). This mechanistic connection directly links the rs17651213 G allele to the molecular basis of 4R tauopathy susceptibility.

The Evidence for Parkinson's Disease and PSP

A large case-control study of 1,762 PD patients and 2,010 controls found that H1/H1 homozygotes — defined using haplotype-tagging variants including rs17651213 — had an odds ratio of 1.46 (95% CI 1.25–1.69, p=8×10⁻⁷) for Parkinson's disease²² A large case-control study of 1,762 PD patients and 2,010 controls found that H1/H1 homozygotes — defined using haplotype-tagging variants including rs17651213 — had an odds ratio of 1.46 (95% CI 1.25–1.69, p=8×10⁻⁷) for Parkinson's disease
The association was consistent across familial and sporadic disease, both sexes, and early- and late-onset subgroups. For PSP, a meta-analysis of 82 case-control studies found H1 haplotype carriers have an odds ratio of 1.96 for PSP and 2.51 for CBD³³ a meta-analysis of 82 case-control studies found H1 haplotype carriers have an odds ratio of 1.96 for PSP and 2.51 for CBD
The most risk-elevated configurations are H1 sub-haplotypes H1d and H1g, which appear to compound the exon 3 splicing shift through additional cis-regulatory variants. H1/H1 homozygotes at rs17651213 are found in approximately 94% of neuropathologically confirmed PSP cases.

Alzheimer's Disease: A Tau-Driven Pathway

A study of 17,996 participants found the H1 haplotype independently associated with Alzheimer's disease risk (OR 1.12, p=0.0025), with the strongest effect in APOE ε4 non-carriers over age 77⁴⁴ A study of 17,996 participants found the H1 haplotype independently associated with Alzheimer's disease risk (OR 1.12, p=0.0025), with the strongest effect in APOE ε4 non-carriers over age 77
This suggests that H1-driven tau isoform imbalance represents a distinct, slower causal pathway to AD that is less dependent on amyloid accumulation than the APOE ε4 pathway. For people without APOE ε4, the rs17651213 G/G genotype may be a more prominent contributor to late-life cognitive decline.

Practical Actions

The rs17651213 G/G genotype identifies the same population-level risk as H1/H1 status at rs1800547, since both SNPs co-define the H1 haplotype and are in very strong linkage disequilibrium. The key difference is that rs17651213 has been shown to be a functional driver — not just a tag — of the splicing difference. The actionable implications focus on neurological monitoring and neuroprotective lifestyle: awareness of early PSP/CBD features (distinct from typical Parkinson's disease) enables accurate diagnosis, and head trauma prevention is especially relevant given that TBI may accelerate tau pathology in H1/H1 individuals already producing tau isoforms skewed toward 4R-prone forms.

Interactions

rs17651213 and rs1800547 work as a mechanistic pair — both must be considered together to fully understand H1-versus-H2 exon 3 splicing differences. They are in very strong LD, so most H1/H1 individuals at rs17651213 will also be H1/H1 at rs1800547 and vice versa. The H1c sub-haplotype tagged by rs242557 adds further risk on top of the baseline H1 genotype. In Alzheimer's disease, the H1/H2 effect interacts with APOE genotype (rs429358), with H1 risk concentrated specifically in APOE ε4 non-carriers.